Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announced the establishment of a U.S. Clinical Advisory Board of renowned cardiologists and cardiovascular researchers. The members will provide clinical and strategic guidance to the Company on the design of its hypertension clinical trial in the U.S. for lead product candidate QGC001, planned for 2017.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/02/QGC_PR_US-Clinical-Advisory-Board_03022016_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
